# Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy

> **NCT06070051** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Virion Therapeutics** · enrollment: 56 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **BIOLOGICAL:** VRON-0200-AdC6
- **BIOLOGICAL:** VRON-0200-AdC7
- **DRUG:** VIR-2218
- **DRUG:** VIR-3434

## Key facts

- **NCT ID:** NCT06070051
- **Lead sponsor:** Virion Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-26
- **Primary completion:** 2026-03-31
- **Final completion:** 2026-03-31
- **Target enrollment:** 56 (ESTIMATED)
- **Last updated:** 2025-05-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06070051

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06070051, "Dose-Escalation Prime/Boost Therapeutic Vaccination Study Of 2 Chimp Adenoviral Vectors in Adults With Chronic HBV On Nucleos(t)Ide Therapy". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06070051. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*